Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Still An Unknown Entity

Altogether, Anavex is unknown, misunderstood, or simply neglected. Only the tiniest fraction of either the retail or institutional investor communities has even heard of some tiny company known as Anavex Life Sciences Corp.

For the few that have, comprehending the unique neurological science of the company is not worth the time to learn (if even possible). Without at least an undergraduate’s training in human biochemistry and cytology, the charts, diagrams, and descriptions of the Anavex sigma-1 receptor agonists and their molecular functions in neurons are simply confusing; if understood to even a slight degree.

Those of us who comprehend the Anavex science and have scrutinized its evidence are prone to wonder why ever more investors aren’t taking AVXL positions.

Simple. Not many, so far, comprehend the science; or don’t see that it will lead eventually to corporate revenues. Anavex is something most equity investors would have no personal reason to accumulate right now.

Wish it weren’t so. But until people start reading “real news, fit to print” about Anavex treatment successes in the New York Times (positive clinical results), nothing significant will change regarding public (investor) perceptions.

Just love the postings here, to the effect, “Well, if Anavex were so great and its science were so good, investors would be grabbing every share. They aren’t. So Anavex is a nothing.”

Common equity investors need to have their due diligence confirmed and authenticated by really smart people, such as the NYT writers. Watch what happens to the share price of AVXL after the first New York Times article on any sort of Anavex clinical trial result. Different world, then. But until then? More of the same, no matter what.